A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study

BACKGROUND: Combined treatment with cisplatin and gemcitabine (CisGem) is the standard of care for patients with advanced biliary tract cancer (ABC). Selumetinib (AZD6244, ARRY-142886) potently and selectively inhibits MEK1/2, an intracellular kinase and has shown activity in ABC. The objective of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bridgewater, John, Lopes, Andre, Beare, Sandra, Duggan, Marian, Lee, Dymphna, Ricamara, Maravic, McEntee, Delyth, Sukumaran, Ajithkumar, Wasan, Harpreet, Valle, Juan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766710/
https://www.ncbi.nlm.nih.gov/pubmed/26912134
http://dx.doi.org/10.1186/s12885-016-2174-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766710/
https://www.ncbi.nlm.nih.gov/pubmed/26912134
http://dx.doi.org/10.1186/s12885-016-2174-8

Ejemplares similares